

Remarks

This Amendment is filed in reply to the final Office Action mailed February 13, 2006 and the Advisory Action mailed on March 21, 2006. Claims 1-24 and 39-60 are pending in the application. The applicant has amended claims 1, 12, 19, 24, 39, 41 and 48 for the purpose of clarifying the invention and canceled claims 11, 40 and 47. Thus, claims 1, 3-10, 12-24 and 39, 41-46 and 48-60 are submitted for reconsideration at this time.

A. Rejections Under 35 U.S.C. § 102

Claims 1, 3-5, 7-14, 17-24, 39-43, 46-50, 53-57 and 60 stand rejected under 35 U.S.C. §102(e) as being anticipated by Knight US Application Publication No. 2002/0099570.

Claim 1, 19, 24 and 39, as amended, now recite that an application to apply for participation in a specific clinical trial is provided to a user that has: 1) met the criteria to participate in any clinical trial based on a comparison of acceptance criteria with the user's profile information; and 2) met the requirements for a specific clinical trial based on their response to a series of targeted questions. The Knight publication nor the provisional application on which the Knight publication claims priority teaches this limitation. The Knight publication and the provisional application 60/227,484, on which the Knight publication claims priority, merely discloses providing trial site contact information and other trial information to the user if the trial is not proprietary and only contact information if it is proprietary. Neither the Knight publication nor the provisional application 60/227,484 teaches providing the user with an application for applying to participate in a specific clinical trial after he has passed initial and trial specific screening.

The claims depending from independent claims 1, 19, 24 and 39 are not anticipated for at least the reasons discussed with respect to claims 1, 19, 24 and 39.

B. Conclusion

In view of the above, it is respectfully submitted that the present invention is allowable over the references relied upon in the Office Action. Accordingly, favorable reconsideration of this case and early issuance of the Notice of Allowance are respectfully requested. Should the Examiner feel further communication would facilitate prosecution, he is urged to call the undersigned at the phone number provided below. The Commissioner is hereby authorized to charge any insufficient fees or credit any overpayment associated with this application to Deposit Account No. 19-5127 (25737.0002).

Respectfully submitted,

Bingham McCutchen LLP

Dated: August 9, 2006

By: 

Chadwick A. Jackson, Reg. No. 46,495
Bingham McCutchen LLP
3000 K Street, NW, Suite 300
Washington, D.C. 20007
(202) 373-6661 Telephone
(202) 295-8478 Facsimile